Pfm Health Sciences, LP Allogene Therapeutics, Inc. Transaction History

Pfm Health Sciences, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$13.13 - $24.52 $10.2 Million - $19 Million	-775,819 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $3.55 Million - $4.67 Million	169,019 Added 27.85%	775,819 $19.9 Million
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $385,752 - $587,907	16,422 Added 2.78%	606,800 $15.8 Million
Q1 2021 May 17, 2021	BUY	$25.79 - $39.02 $15.2 Million - $23 Million	590,378 New	590,378 $20.8 Million
Q4 2020 Feb 16, 2021	SELL	$25.24 - $43.45 $5.66 Million - $9.74 Million	-224,266 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$32.38 - $44.96 $7.26 Million - $10.1 Million	224,266 New	224,266 $8.46 Million
Q1 2019 May 15, 2019	SELL	$24.82 - $32.54 $15.3 Million - $20.1 Million	-617,193 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $13.9 Million - $20.6 Million	617,193 New	617,193 $16.6 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.